3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
NET
19
Gastrointestinal
19
Endocrine
19
Lymphoid
2
CNS
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Dermatologic
1
Breast
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
310
Lymphoma
305
Lymphoma, Non-Hodgkin
226
Lymphoma, Large B-Cell, Diffuse
220
Lymphoma, Follicular
200
Leukemia, Lymphocytic, Chronic, B-Cell
168
Lymphoma, B-Cell
148
Recurrence
124
Burkitt Lymphoma
117
Lymphoma, Mantle-Cell
112
Leukemia, Myeloid, Acute
106
Leukemia
102
Hodgkin Disease
102
Multiple Myeloma
95
Lymphoma, B-Cell, Marginal Zone
87
Neoplasms
80
Myelodysplastic Syndromes
69
Lymphoma, T-Cell, Peripheral
62
Hematologic Neoplasms
61
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
58
Lymphoma, T-Cell
51
Lymphoma, T-Cell, Cutaneous
44
Waldenstrom Macroglobulinemia
41
Leukemia, Biphenotypic, Acute
35
Mycosis Fungoides
31
Lymphoproliferative Disorders
30
Leukemia, B-Cell
30
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
29
Breast Neoplasms
28
Myeloproliferative Disorders
26
Interventions
pasireotide
1
amino-acid, glucose, and electrolyte solution
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Gastro-enteropancreatic neuroendocrine tumor
×
Lymphoid
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled
NCT06784752
2026-04-30
NETTER-3
Novartis
Phase 3
Recruiting
240 enrolled